Vertex posts positive data from cystic fibrosis triple combo trials
November 27, 2018 at 12:44 PM EST
Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients of cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.